Royalty Pharma declares third quarter 2026 dividend

Q: What dividend did Royalty Pharma (RPRX) declare for the third quarter of 2026?

Royalty Pharma declared a $0.235 per Class A ordinary share dividend for the third quarter of 2026. According to Royalty Pharma, this dividend will be paid in cash to eligible shareholders based on the announced record date and payment schedule.

Q: When is the Royalty Pharma (RPRX) Q3 2026 dividend payment date?

The Q3 2026 dividend for Royalty Pharma is payable on September 10, 2026 . According to Royalty Pharma, shareholders who are on the company’s register as of the record date will receive the dividend on this payment date.

Q: What is the record date for Royalty Pharma (RPRX) third quarter 2026 dividend?

The record date for Royalty Pharma’s Q3 2026 dividend is August 14, 2026 . According to Royalty Pharma, shareholders of record at the close of business on this date will be entitled to receive the $0.235 per share dividend.

Q: Which Royalty Pharma (RPRX) shares are eligible for the Q3 2026 dividend?

The Q3 2026 dividend applies to Class A ordinary shares of Royalty Pharma. According to Royalty Pharma, each Class A ordinary share outstanding on the August 14, 2026 record date will be entitled to receive a cash dividend of $0.235.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Positive)

Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) announced that its board of directors has approved a third quarter 2026 dividend of $0.235 per Class A ordinary share. The dividend is scheduled to be paid on September 10, 2026 to shareholders of record as of August 14, 2026.

According to Royalty Pharma, the company is the largest buyer of biopharmaceutical royalties and a major funder of industry innovation. Its portfolio includes royalties on more than 35 commercial products and 19 development-stage product candidates across leading biopharmaceutical companies.

Positive

Q3 2026 dividend declared at $0.235 per Class A share, payable September 10, 2026

Negative

None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

07/17/2026 - 04:15 PM

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.

The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.

About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com

FAQ

What dividend did Royalty Pharma (RPRX) declare for the third quarter of 2026?

Royalty Pharma declared a $0.235 per Class A ordinary share dividend for the third quarter of 2026. According to Royalty Pharma, this dividend will be paid in cash to eligible shareholders based on the announced record date and payment schedule.

When is the Royalty Pharma (RPRX) Q3 2026 dividend payment date?

The Q3 2026 dividend for Royalty Pharma is payable on September 10, 2026. According to Royalty Pharma, shareholders who are on the company’s register as of the record date will receive the dividend on this payment date.

What is the record date for Royalty Pharma (RPRX) third quarter 2026 dividend?

The record date for Royalty Pharma’s Q3 2026 dividend is August 14, 2026. According to Royalty Pharma, shareholders of record at the close of business on this date will be entitled to receive the $0.235 per share dividend.

Which Royalty Pharma (RPRX) shares are eligible for the Q3 2026 dividend?

The Q3 2026 dividend applies to Class A ordinary shares of Royalty Pharma. According to Royalty Pharma, each Class A ordinary share outstanding on the August 14, 2026 record date will be entitled to receive a cash dividend of $0.235.

What does Royalty Pharma’s business model involve for RPRX investors?

Royalty Pharma’s model focuses on buying biopharmaceutical royalties and funding innovation. According to Royalty Pharma, its portfolio includes royalties on more than 35 commercial products and 19 development-stage candidates, generating payments tied directly to top-line sales of partnered therapies.